{
    "nct_id": "NCT03472586",
    "official_title": "Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma",
    "inclusion_criteria": "* Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is >= 10 mm in longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI)\n* The total volume of the tumors must be less than 50% of the liver volume\n* Willingness and ability to give informed consent\n* Agreement to access archival tissue or agreement for tumor biopsy prior to treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1\n* Serum creatinine =< 2.0 mg/dl\n* Granulocyte count >= 1000/mm^3\n* Platelet count >= 100,000/mm^3\n* Bilirubin =< 2.0 mg/ml\n* Albumin >= 3.0 g/dl\n* Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN)\n* Alkaline phosphatase less than 1.5 times ULN (grade 1)\n* Women must not be pregnant or breast-feeding\n* Women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 23 weeks after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 31 weeks after the last dose of nivolumab and/or ipilimumab\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Failure to meet any of the criteria set forth in the inclusion criteria section\n* Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody\n* Previous liver-directed treatments including chemoembolization, radiosphere, hepatic arterial perfusion, or drug-eluting beads; liver resection and focal ablation are permitted\n* Presence of symptomatic liver failure including ascites and hepatic encephalopathy\n* Presence of untreated brain metastases; if patients have had previous treatment for the brain metastasis, an MRI or CT scan of the brain must confirm the stabilization of the brain metastasis for more than 2 months\n* Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry\n* Presence of any other medical complication that implies survival of less than six months\n* Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding\n* Significant allergic reaction to contrast dye or granulocyte-macrophage colony-stimulating (GM-CSF)\n* Immunosuppressive treatments within 4 weeks prior to embolization, unless prednisone =< 5 mg or equivalent\n* Pregnancy or breast-feeding women\n* Patients with active hepatitis with serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) equal or greater than 5 times normal\n* Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy\n* Positive for known human immunodeficiency virus (HIV) Infection\n* Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis\n* Active infection\n* Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis, but not including hypothyroidism or psoriasis if condition has been stable for 2 months or greater",
    "miscellaneous_criteria": ""
}